A number of research firms have changed their ratings and price targets for Mirati Therapeutics (NASDAQ: MRTX):

  • 12/1/2017 – Mirati Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 11/22/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $18.00 price target on the stock.
  • 11/16/2017 – Mirati Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 11/14/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock, down previously from $20.00.
  • 11/14/2017 – Mirati Therapeutics was upgraded by analysts at Leerink Swann from a “market perform” rating to an “outperform” rating. They now have a $9.00 price target on the stock.
  • 11/7/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright.
  • 11/7/2017 – Mirati Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. “
  • 10/12/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at SunTrust Banks, Inc.. They now have a $13.00 price target on the stock.
  • 10/12/2017 – Mirati Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

Mirati Therapeutics, Inc. (MRTX) traded down $0.65 during trading on Tuesday, reaching $16.10. 548,300 shares of the company’s stock traded hands, compared to its average volume of 545,325. Mirati Therapeutics, Inc. has a 1 year low of $2.70 and a 1 year high of $19.25.

Mirati Therapeutics (NASDAQ:MRTX) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.16. equities research analysts expect that Mirati Therapeutics, Inc. will post -2.77 earnings per share for the current year.

In other Mirati Therapeutics news, SVP Jamie Christensen sold 7,499 shares of the business’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $14.00, for a total value of $104,986.00. Following the completion of the sale, the senior vice president now directly owns 10,169 shares of the company’s stock, valued at $142,366. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Venbio Select Advisor Llc bought 650,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was acquired at an average cost of $13.00 per share, with a total value of $8,450,000.00. The disclosure for this purchase can be found here. In the last quarter, insiders sold 23,544 shares of company stock worth $365,826. Company insiders own 5.10% of the company’s stock.

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Receive News & Ratings for Mirati Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.